Results 111 to 120 of about 6,357 (207)

Publication Only

HemaSphere, Volume 9, Issue S1, June 2025.
wiley   +1 more source

Pharmacoeconomic analysis of using the darbepoetin alfa to correct anemia in patients with chronic renal failure who are on hemodialysis or peritoneal dialysis

Качественная клиническая практика, 2018
Goal: to conduct pharmacoeconomic analysis of using the darbepoetin alfa (Aranesp) and other erythropoiesis-stimulating agents for anemia correction in patients on hemodialysis or peritoneal dialysis. Methodology.
I. S. Krysanov, T. S. Fakeeva, O. N. Kotenko   +2 more
doaj  

The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study. [PDF]

Indian J Hematol Blood Transfus, 2022
Ak MA, Sahip B, Geduk A, Ucar MA, Kale H, Hacibekiroglu T, Polat MG, Kalpakci Y, Bolaman AZ, Guvenc B, Ertop S.   +10 more
europepmc   +1 more source

Estudio retrospectivo de la influencia de la respuesta al tratamiento quimioterápico de primera línea en pacientes con cáncer no microcítico de pulmón sobre la respuesta a la administración de factores estimulantes de la eritropoyesis en la anemia inducida por quimioterapia [PDF]

, 2012
S'analitza de manera retrospectiva la relació entre la resposta a la quimioteràpia i la milloria de l'anèmia induïda per la quimioteràpia amb factors estimulants de la eritropoesi en 57 pacients amb carcinoma no microcític de pulmó avançat que ...
Blasco Mollá, Sara, Universitat Autònoma de Barcelona. Departament de Medicina, Universitat Autònoma de Barcelona. Facultat de Medicina   +2 more
core  

Correction to: A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure. [PDF]

BMC Nephrol, 2022
Lim SK, Goh BL, Visvanathan R, Kim SH, Jeon JS, Kim SG, Chang JH, Lim CS, Morad Z.   +8 more
europepmc   +1 more source

Understanding the market dynamics of biosimilars

, 2016
Biosimilars represent an attractive market opportunity in the pharmaceutical industry. In order to understand the underlying market dynamics and to identify the success factors of the biosimilars market, a PEST (political, economic, social, technological)
Dassow, J. (Jonas), Daubenfeld, T. (Thorsten), Keßler, M. (Maximilian), Schulze, J. (Jonas)   +3 more
core  

Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.

J Am Soc Nephrol, 2022
Fishbane S, Pollock CA, El-Shahawy M, Escudero ET, Rastogi A, Van BP, Frison L, Houser M, Pola M, Little DJ, Guzman N, Pergola PE.   +11 more
europepmc   +1 more source

Arterial and venous thrombosis complicating coronary artery bypass grafting after use of epoetin alfa-epbx. [PDF]

JTCVS Tech, 2020
Murillo-Berlioz A, Guinn NR, Levy JH, Milano CA.   +3 more
europepmc   +1 more source

HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience

Drug Design, Development and Therapy, 2017
Frank Dellanna,1 David Goldsmith,2 Andriy Krendyukov,3 Andreas Seidl,4 Nadja Höbel,5 Christian Combe6,7 1MVZ Davita Rhein-Ruhr, Düsseldorf, Germany; 2Division of Nephrology, Guy’s and St Thomas’ Hospitals, London, UK; 3Hematology ...
Dellanna F, Goldsmith D, Krendyukov A, Seidl A, Höbel N, Combe C   +5 more
doaj